Advertisement

International Orthopaedics

, Volume 41, Issue 10, pp 2053–2059 | Cite as

The efficacy and safety of multiple-dose intravenous tranexamic acid on blood loss following total knee arthroplasty: a randomized controlled trial

  • Yiting Lei
  • Jinwei Xie
  • Bin Xu
  • Xiaowei Xie
  • Qiang Huang
  • Fuxing PeiEmail author
Original Paper

Abstract

Purpose

To assess the efficacy and safety of multiple-dose intravenous tranexamic acid (IV-TXA) on blood loss following total knee arthroplasty (TKA).

Methods

One hundred fifty nine patients received one bolus of IV-TXA before skin incision and two boluses three and six hours later (group A), or another bolus nine hours later (group B), or another two boluses nine and 12 hours later (group C). The primary outcomes were total blood loss (TBL), hidden blood loss (HBL), and maximum haemoglobin (Hb) drop. Other outcome measurements such as fibrinolysis parameters [fibrin(−ogen) degradation products (FDP), D-dimer], inflammatory factors [interleukin-6 (IL-6)], transfusion rate, range of motion (ROM), length of hospital stay (LOH), and complications were also recorded and compared.

Results

The mean TBL, HBL and maximum Hb drop in group C (p < 0.001, p < 0.001, p = 0.025) and group B (p = 0.025, p = 0.025, p = 0.044) were lower than those in group A. FDP and D-Dimer in group C was lower than in group A and B on post-operative day one. IL-6 in group A, B and C showed a downward tendency on post-operative days one and three (POD1 and POD3). Moreover, the ROM and LOH were better in group C. No episodes of transfusion or deep venous thrombosis (DVT) were detected in all groups.

Conclusions

The 5-dose TXA regimen can further reduce the blood loss, diminish the maximum Hb drop, minimize inflammation, enhance mobility, and shorten LOS following TKA, without increasing the risk of complications. An additional dose could be requisite when fibrinolysis maintains after 5-dose regimen has already been performed.

Level of evidence: I.

Keywords

Tranexamic acid Total knee arthroplasty Blood loss Multiple-dose treatment Randomized controlled trial 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare no conflict of interest.

Funding

This study was funded by the National Health and Family Planning Commission of the People’s Republic of China (CN) program (201302007).

Ethical approval

The trial was approved by the institutional review board and registered the International Clinical Trial Registry (ChiCTR-INR-16009288).

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Xie J, Ma J, Yao H, Yue C, Pei F (2016) Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss after primary total knee arthroplasty without tourniquet: a randomized clinical trial. J Arthroplast. doi: 10.1016/j.arth.2016.04.034
  2. 2.
    Hogan CA, Golightly LK, Phong S, Dayton MR, Lyda C, Barber GR (2016) Perioperative blood loss in total hip and knee arthroplasty: outcomes associated with intravenous tranexamic acid use in an academic medical center. SAGE Open Med 4:2050312116637024. doi: 10.1177/2050312116637024 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Holt JB, Miller BJ, Callaghan JJ, Clark CR, Willenborg MD, Noiseux NO (2016) Minimizing blood transfusion in total hip and knee arthroplasty through a multimodal approach. J Arthroplast 31(2):378–382. doi: 10.1016/j.arth.2015.08.025 CrossRefGoogle Scholar
  4. 4.
    Rineau E, Chaudet A, Chassier C, Bizot P, Lasocki S (2016) Implementing a blood management protocol during the entire perioperative period allows a reduction in transfusion rate in major orthopedic surgery: a before-after study. Transfusion 56(3):673–681. doi: 10.1111/trf.13468 CrossRefPubMedGoogle Scholar
  5. 5.
    Liu KL, Chen IH, Wen SH (2016) Low dose tranexamic acid reduces blood transfusion rate after total knee arthroplasty: a population-based study in Taiwan. J Formos Med Assoc. doi: 10.1016/j.jfma.2015.12.012
  6. 6.
    Oremus K (2015) Tranexamic acid for the reduction of blood loss in total knee arthroplasty. Ann Transl Med 3(Suppl 1):S40. doi: 10.3978/j.issn.2305-5839.2015.03.35 PubMedPubMedCentralGoogle Scholar
  7. 7.
    Maniar RN, Kumar G, Singhi T, Nayak RM, Maniar PR (2012) Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients. Clin Orthop Relat Res 470(9):2605–2612. doi: 10.1007/s11999-012-2310-y CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Akgul T, Buget M, Salduz A, Edipoglu IS, Ekinci M, Kucukay S, Sen C (2016) Efficacy of preoperative administration of single high dose intravenous tranexamic acid in reducing blood loss in total knee arthroplasty: a prospective clinical study. Acta Orthop Traumatol Turc. doi: 10.1016/j.aott.2016.06.007
  9. 9.
    Hourlier H, Reina N, Fennema P (2015) Single dose intravenous tranexamic acid as effective as continuous infusion in primary total knee arthroplasty: a randomised clinical trial. Arch Orthop Trauma Surg 135(4):465–471. doi: 10.1007/s00402-015-2168-z CrossRefPubMedGoogle Scholar
  10. 10.
    Blanie A, Bellamy L, Rhayem Y, Flaujac C, Samama CM, Fontenay M, Rosencher N (2013) Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study. Thromb Res 131(1):e6–e11. doi: 10.1016/j.thromres.2012.11.006 CrossRefPubMedGoogle Scholar
  11. 11.
    Huang Z, Ma J, Shen B, Pei F (2014) Combination of intravenous and topical application of tranexamic acid in primary total knee arthroplasty: a prospective randomized controlled trial. J Arthroplast 29(12):2342–2346. doi: 10.1016/j.arth.2014.05.026 CrossRefGoogle Scholar
  12. 12.
    Yue C, Kang P, Yang P, Xie J, Pei F (2014) Topical application of tranexamic acid in primary total hip arthroplasty: a randomized double-blind controlled trial. J Arthroplast 29(12):2452–2456. doi: 10.1016/j.arth.2014.03.032 CrossRefGoogle Scholar
  13. 13.
    Serrano Mateo L, Goudarz Mehdikhani K, Caceres L, Lee YY, Gonzalez Della Valle A (2016) Topical tranexamic acid may improve early functional outcomes of primary total knee arthroplasty. J Arthroplast 31(7):1449–1452. doi: 10.1016/j.arth.2016.01.009 CrossRefGoogle Scholar
  14. 14.
    Li B, Wen Y, Wu H, Qian Q, Lin X, Zhao H (2009) The effect of tourniquet use on hidden blood loss in total knee arthroplasty. Int Orthop 33(5):1263–1268. doi: 10.1007/s00264-008-0647-3 CrossRefPubMedGoogle Scholar
  15. 15.
    Wang S, Gao X, An Y (2017) Topical versus intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials. Int Orthop 41(4):739–748. doi: 10.1007/s00264-016-3296-y CrossRefPubMedGoogle Scholar
  16. 16.
    Whiting DR, Duncan CM, Sierra RJ, Smith HM (2015) Tranexamic acid benefits total joint arthroplasty patients regardless of preoperative hemoglobin value. J Arthroplast 30(12):2098–2101. doi: 10.1016/j.arth.2015.05.050 CrossRefGoogle Scholar
  17. 17.
    Panteli M, Papakostidis C, Dahabreh Z, Giannoudis PV (2013) Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis. Knee 20(5):300–309. doi: 10.1016/j.knee.2013.05.014 CrossRefPubMedGoogle Scholar
  18. 18.
    Iwai T, Tsuji S, Tomita T, Sugamoto K, Hideki Y, Hamada M (2013) Repeat-dose intravenous tranexamic acid further decreases blood loss in total knee arthroplasty. Int Orthop 37(3):441–445. doi: 10.1007/s00264-013-1787-7 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Morais S, Ortega-Andreu M, Rodriguez-Merchan EC, Padilla-Eguiluz NG, Perez-Chrzanowska H, Figueredo-Zalve R, Gomez-Barrena E (2014) Blood transfusion after primary total knee arthroplasty can be significantly minimised through a multimodal blood-loss prevention approach. Int Orthop 38(2):347–354. doi: 10.1007/s00264-013-2188-7 CrossRefPubMedGoogle Scholar
  20. 20.
    Jimenez JJ, Iribarren JL, Brouard M, Hernandez D, Palmero S, Jimenez A, Lorente L, Machado P, Borreguero JM, Raya JM, Martin B, Perez R, Martinez R, Mora ML (2011) Safety and effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: a randomized double-blind, dose-dependent, phase IV clinical trial. J Cardiothorac Surg 6:138. doi: 10.1186/1749-8090-6-138 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Robson SC, Shephard EG, Kirsch RE (1994) Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 86(2):322–326CrossRefPubMedGoogle Scholar
  22. 22.
    Bergin PF, Doppelt JD, Kephart CJ, Benke MT, Graeter JH, Holmes AS, Haleem-Smith H, Tuan RS, Unger AS (2011) Comparison of minimally invasive direct anterior versus posterior total hip arthroplasty based on inflammation and muscle damage markers. J Bone Joint Surg Am 93(15):1392–1398. doi: 10.2106/jbjs.j.00557 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Gilbody J, Dhotar HS, Perruccio AV, Davey JR (2014) Topical tranexamic acid reduces transfusion rates in total hip and knee arthroplasty. J Arthroplast 29(4):681–684. doi: 10.1016/j.arth.2013.09.005 CrossRefGoogle Scholar
  24. 24.
    Xie J, Ma J, Kang P, Zhou Z, Shen B, Yang J, Pei F (2015) Does tranexamic acid alter the risk of thromboembolism following primary total knee arthroplasty with sequential earlier anticoagulation? A large, single center, prospective cohort study of consecutive cases. Thromb Res 136(2):234–238. doi: 10.1016/j.thromres.2015.05.014 CrossRefPubMedGoogle Scholar
  25. 25.
    Fillingham YA, Kayupov E, Plummer DR, Moric M, Gerlinger TL, Della Valle CJ (2016) The James A. Rand young investigator’s award: a randomized controlled trial of oral and intravenous tranexamic acid in total knee arthroplasty: the same efficacy at lower cost? J Arthroplast 31(9 Suppl):26–30. doi: 10.1016/j.arth.2016.02.081 CrossRefGoogle Scholar
  26. 26.
    Wasko MK, Bobecka-Wesolowska K, Tomasiuk R, Kowalczewski J (2015) Measurement of the inflammatory response in the early postoperative period after hip and knee arthroplasty. Clin Chem Lab Med 53(11):1785–1792. doi: 10.1515/cclm-2014-1055 CrossRefPubMedGoogle Scholar

Copyright information

© SICOT aisbl 2017

Authors and Affiliations

  • Yiting Lei
    • 1
  • Jinwei Xie
    • 1
  • Bin Xu
    • 1
  • Xiaowei Xie
    • 1
  • Qiang Huang
    • 1
  • Fuxing Pei
    • 1
    Email author
  1. 1.Department of Orthopaedics, West China HospitalSichuan UniversityChengduPeople’s Republic of China

Personalised recommendations